TWI485150B - 三唑并吡啶化合物及其作為脯胺醯基羥化酶抑制劑或紅血球生成素生產誘導劑之作用 - Google Patents

三唑并吡啶化合物及其作為脯胺醯基羥化酶抑制劑或紅血球生成素生產誘導劑之作用 Download PDF

Info

Publication number
TWI485150B
TWI485150B TW099123410A TW99123410A TWI485150B TW I485150 B TWI485150 B TW I485150B TW 099123410 A TW099123410 A TW 099123410A TW 99123410 A TW99123410 A TW 99123410A TW I485150 B TWI485150 B TW I485150B
Authority
TW
Taiwan
Prior art keywords
compound
group
pharmaceutically acceptable
acceptable salt
alkyl
Prior art date
Application number
TW099123410A
Other languages
English (en)
Chinese (zh)
Other versions
TW201105671A (en
Inventor
三谷育生
生越洋介
松井拓也
橫田正宏
寺下正和
元田大
上山和人
阿部博行
堀田隆宏
伊東敬史
Original Assignee
日本煙草產業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日本煙草產業股份有限公司 filed Critical 日本煙草產業股份有限公司
Publication of TW201105671A publication Critical patent/TW201105671A/zh
Application granted granted Critical
Publication of TWI485150B publication Critical patent/TWI485150B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
TW099123410A 2009-07-17 2010-07-16 三唑并吡啶化合物及其作為脯胺醯基羥化酶抑制劑或紅血球生成素生產誘導劑之作用 TWI485150B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009169565 2009-07-17

Publications (2)

Publication Number Publication Date
TW201105671A TW201105671A (en) 2011-02-16
TWI485150B true TWI485150B (zh) 2015-05-21

Family

ID=43449466

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099123410A TWI485150B (zh) 2009-07-17 2010-07-16 三唑并吡啶化合物及其作為脯胺醯基羥化酶抑制劑或紅血球生成素生產誘導劑之作用

Country Status (27)

Country Link
US (3) US8283465B2 (cg-RX-API-DMAC7.html)
EP (3) EP3594213A1 (cg-RX-API-DMAC7.html)
JP (9) JP5021797B2 (cg-RX-API-DMAC7.html)
KR (5) KR20180042443A (cg-RX-API-DMAC7.html)
CN (1) CN102471337B (cg-RX-API-DMAC7.html)
AR (1) AR077417A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010271732B2 (cg-RX-API-DMAC7.html)
CA (1) CA2768505C (cg-RX-API-DMAC7.html)
CO (1) CO6430426A2 (cg-RX-API-DMAC7.html)
DK (1) DK2455381T5 (cg-RX-API-DMAC7.html)
ES (1) ES2477968T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20140705T1 (cg-RX-API-DMAC7.html)
IL (1) IL217541A (cg-RX-API-DMAC7.html)
ME (1) ME01858B (cg-RX-API-DMAC7.html)
MX (1) MX2012000766A (cg-RX-API-DMAC7.html)
MY (1) MY160814A (cg-RX-API-DMAC7.html)
NZ (1) NZ598242A (cg-RX-API-DMAC7.html)
PE (1) PE20120629A1 (cg-RX-API-DMAC7.html)
PL (1) PL2455381T3 (cg-RX-API-DMAC7.html)
PT (1) PT2455381E (cg-RX-API-DMAC7.html)
RS (1) RS53499B1 (cg-RX-API-DMAC7.html)
RU (1) RU2538963C2 (cg-RX-API-DMAC7.html)
SG (1) SG178049A1 (cg-RX-API-DMAC7.html)
SI (1) SI2455381T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201500122B (cg-RX-API-DMAC7.html)
TW (1) TWI485150B (cg-RX-API-DMAC7.html)
WO (1) WO2011007856A1 (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283465B2 (en) * 2009-07-17 2012-10-09 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
JP2011168582A (ja) * 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
HK1215179A1 (zh) 2012-11-26 2016-08-19 国立大学法人东北大学 促红细胞生成素表达增强剂
AP2015008502A0 (en) 2012-12-24 2015-06-30 Cadila Healthcare Ltd Novel quinolone derivatives
HUE066123T2 (hu) 2013-06-13 2024-07-28 Akebia Therapeutics Inc Készítmények és módszerek anémia kezelésére
RU2534804C1 (ru) * 2013-08-05 2014-12-10 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ, ПРОЯВЛЯЮЩИЕ СВОЙСТВА АНТАГОНИСТОВ АДЕНОЗИНОВЫХ А2А РЕЦЕПТОРОВ, И ИХ ПРИМЕНЕНИЕ
SI3052096T1 (en) 2013-10-03 2018-04-30 Kura Oncology, Inc. EAQ inhibitors and application procedures
CA2959688C (en) 2014-09-02 2024-02-27 Sunshine Lake Pharma Co., Ltd. Quinolone compounds and their use to treat diseases related to hypoxia inducible factor and/or erythropoietin
JP2018039733A (ja) * 2014-12-22 2018-03-15 株式会社富士薬品 新規複素環誘導体
GB201504565D0 (en) * 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
CN106146395B (zh) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
EP4667059A3 (en) 2015-05-28 2026-04-08 Japan Tobacco Inc. Method for treating or preventing diabetic nephropathy
MX2019006083A (es) * 2016-11-25 2019-07-10 Japan Tobacco Inc Metodo para la produccion de compuesto de triazolopiridina.
JP7142406B2 (ja) 2017-05-09 2022-09-27 カインド ファーマシューティカル インドリジン誘導体及びその医学的応用
SG11202003005PA (en) * 2017-10-04 2020-04-29 Japan Tobacco Inc Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof
CN107739378A (zh) * 2017-11-14 2018-02-27 杭州安道药业有限公司 吲哚嗪衍生物及其在医药上的应用
DK3808747T3 (da) * 2018-09-13 2025-02-03 Kissei Pharmaceutical Imidazopyridinon-forbindelse
CN110105355B (zh) * 2019-05-24 2021-09-21 烟台大学 一种1,2,3-三唑-[1,5-a]并喹啉类化合物的制备方法
JP7566008B2 (ja) * 2020-03-11 2024-10-11 キッセイ薬品工業株式会社 イミダゾピリジノン化合物又はその塩の結晶
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
CN113387948B (zh) * 2021-02-06 2022-06-10 成都诺和晟泰生物科技有限公司 一种稠环杂芳基衍生物及其药物组合物和治疗方法及用途
BR112023018949A2 (pt) 2021-03-19 2023-10-17 Zydus Lifesciences Ltd Composto, uso do mesmo para tratar anemia falciforme e composição farmacêutica compreendendo o referido composto
CN115197210A (zh) * 2021-04-06 2022-10-18 广东东阳光药业有限公司 一种酸的晶型及其制备方法
EP4347022A1 (en) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
CN113582843A (zh) * 2021-09-09 2021-11-02 无锡捷化医药科技有限公司 一种5-氯-2-氟-3-羟基苯甲酸乙酯的制备方法
CN116496269B (zh) * 2021-12-02 2025-02-28 苏中药业集团股份有限公司 一种脯氨酰羟化酶抑制剂及其用途
CN114031619A (zh) * 2021-12-17 2022-02-11 山东汇海医药化工有限公司 一种图卡替尼中间体的制备方法
CN117327066A (zh) * 2022-06-30 2024-01-02 上海济煜医药科技有限公司 一种新多晶型、其制备方法及其用于制备药物的用途
EP4578855A1 (en) * 2022-09-19 2025-07-02 Suzhong Pharmaceutical Group Co., Ltd. Prolyl hydroxylase inhibitor and use thereof
TWI905781B (zh) * 2023-06-02 2025-11-21 大陸商蘇中藥業集團股份有限公司 脯胺醯羥化酶抑制劑及其用途
TW202506675A (zh) * 2023-08-08 2025-02-16 美商富曼西公司 用於防治和對抗無脊椎有害生物的連接的雙環化合物
KR20260061246A (ko) 2023-10-24 2026-05-06 카인드 파마슈티컬 저산소증 유도인자-프로릴히드록시라제 억제제를 함유하는 장시간 작용형 경구 의약품 및 그 사용
CN117486878B (zh) * 2023-10-27 2026-05-05 扬州市普林斯医药科技有限公司 一种恩那司他的制备方法
WO2025137158A1 (en) * 2023-12-19 2025-06-26 Akebia Therapeutics, Inc. Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as phd inhibitor compounds, compositions, and methods of use
CN119700755B (zh) * 2024-02-05 2026-01-30 深圳信立泰药业股份有限公司 化合物在制备预防和/或治疗高原病的药物中的应用
WO2025167738A1 (zh) * 2024-02-05 2025-08-14 深圳信立泰药业股份有限公司 化合物在制备治疗非髓系恶性肿瘤患者的贫血药物中的应用
CN119039291A (zh) * 2024-09-09 2024-11-29 南京药坦生物科技有限公司 一种恩那度司他中间体及其制备方法
CN122036726A (zh) * 2026-04-20 2026-05-15 天津辰欣药物研究有限公司 一种三唑并吡啶化合物的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213335A1 (en) * 2006-03-07 2007-09-13 Fitch Duke M Prolyl Hydroxylase Inhibitors
US20070299086A1 (en) * 2006-06-26 2007-12-27 The Procter & Gamble Company Prolyl hydroxylase inhibitors and methods of use
WO2008089052A2 (en) * 2007-01-12 2008-07-24 Smithkline Beecham Corporation N-substituted glycine derivatives: hydroxylase inhibitors
WO2009073497A2 (en) * 2007-11-30 2009-06-11 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6355653B1 (en) * 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
BR0213172A (pt) * 2001-10-08 2004-09-14 Hoffmann La Roche Amida do ácido 8-amino-[1,2,4]triazolo[1,5-a]piridina-6-carboxìlico
US7544699B2 (en) 2003-08-08 2009-06-09 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
MX2007001431A (es) * 2004-08-05 2007-04-02 Hoffmann La Roche Derivados de indol, de indazol o de indolina.
FR2889383A1 (fr) * 2005-08-01 2007-02-02 France Telecom Procede et dispositif de detection pour systeme mimo, systeme mimo, programme et support d'information
JP2009537558A (ja) * 2006-05-16 2009-10-29 スミスクライン・ビーチャム・コーポレイション プロリルヒドロキシラーゼ阻害剤
TWI394747B (zh) 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
AU2007272009A1 (en) 2006-07-12 2008-01-17 Syngenta Limited Triazolopyridine derivatives as herbicides
EP2142509B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
CA2685219C (en) 2007-05-04 2012-06-19 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
EP2172447A4 (en) 2007-07-03 2011-08-24 Astellas Pharma Inc amide
JP2011505367A (ja) * 2007-11-30 2011-02-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
US8324241B2 (en) * 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
WO2009134850A1 (en) 2008-04-30 2009-11-05 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
CN102112475A (zh) 2008-05-29 2011-06-29 西特里斯药业公司 作为沉默调节蛋白调节剂的咪唑并吡啶和相关的类似物
PL2379548T3 (pl) 2008-12-19 2016-08-31 Leo Pharma As Triazolopirydyny jako inhibitory fosfodiesterazy do leczenia chorób skórnych
US8283465B2 (en) * 2009-07-17 2012-10-09 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213335A1 (en) * 2006-03-07 2007-09-13 Fitch Duke M Prolyl Hydroxylase Inhibitors
US20070299086A1 (en) * 2006-06-26 2007-12-27 The Procter & Gamble Company Prolyl hydroxylase inhibitors and methods of use
WO2008089052A2 (en) * 2007-01-12 2008-07-24 Smithkline Beecham Corporation N-substituted glycine derivatives: hydroxylase inhibitors
WO2009073497A2 (en) * 2007-11-30 2009-06-11 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors

Also Published As

Publication number Publication date
EP2455381A1 (en) 2012-05-23
CA2768505C (en) 2018-06-12
JP2015003933A (ja) 2015-01-08
AR077417A1 (es) 2011-08-24
CA2768505A1 (en) 2011-01-20
DK2455381T5 (en) 2015-02-09
JP2011037841A (ja) 2011-02-24
EP2746282A1 (en) 2014-06-25
EP2455381B1 (en) 2014-05-28
KR101850661B1 (ko) 2018-04-19
CN102471337B (zh) 2014-12-10
JP2012144571A (ja) 2012-08-02
JP6434575B2 (ja) 2018-12-05
NZ598242A (en) 2013-09-27
DK2455381T3 (da) 2014-07-21
RU2538963C2 (ru) 2015-01-10
HRP20140705T1 (hr) 2014-09-12
MY160814A (en) 2017-03-31
SI2455381T1 (sl) 2014-08-29
ME01858B (me) 2014-12-20
US8283465B2 (en) 2012-10-09
US20130096155A1 (en) 2013-04-18
US20110077267A1 (en) 2011-03-31
ES2477968T3 (es) 2014-07-18
IL217541A0 (en) 2012-02-29
EP2455381B9 (en) 2014-10-22
HK1168346A1 (en) 2012-12-28
AU2010271732A1 (en) 2012-03-08
KR20120051704A (ko) 2012-05-22
JP2016040321A (ja) 2016-03-24
PE20120629A1 (es) 2012-05-30
MX2012000766A (es) 2012-02-08
CO6430426A2 (es) 2012-04-30
KR20230165366A (ko) 2023-12-05
SMT201500122B (it) 2015-07-09
RS53499B1 (sr) 2015-02-27
JP2024091878A (ja) 2024-07-05
JP2020111612A (ja) 2020-07-27
US20160145254A1 (en) 2016-05-26
IL217541A (en) 2014-07-31
CN102471337A (zh) 2012-05-23
TW201105671A (en) 2011-02-16
BR112012001157A2 (pt) 2016-02-23
PL2455381T3 (pl) 2014-10-31
SG178049A1 (en) 2012-03-29
KR20260012830A (ko) 2026-01-27
JP2019019144A (ja) 2019-02-07
KR101706803B1 (ko) 2017-02-14
PT2455381E (pt) 2014-06-24
KR20180042443A (ko) 2018-04-25
RU2012105467A (ru) 2013-08-27
KR20170018105A (ko) 2017-02-15
WO2011007856A1 (ja) 2011-01-20
JP2022126843A (ja) 2022-08-30
JP5021797B2 (ja) 2012-09-12
EP3594213A1 (en) 2020-01-15
AU2010271732B2 (en) 2016-08-25
JP2017214404A (ja) 2017-12-07
EP2455381A4 (en) 2012-12-12
ES2477968T9 (es) 2014-11-13

Similar Documents

Publication Publication Date Title
JP6434575B2 (ja) トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用
TWI491591B (zh) 吲哚化合物及其醫藥用途
US20200017492A1 (en) Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
JP2014193887A (ja) ピリジノニルｐｄｋ１阻害剤
JP7822578B2 (ja) Ｃｄｋキナーゼ阻害剤として使用される化合物およびその応用
US20230027075A1 (en) Sulfonamide compounds targeting cd73 and adenosine receptors
KR20190117807A (ko) 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용
HK1168346B (en) Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer